

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. §208(b)(3)

James Neaton, Ph.D.

Committees: Cardiovascular and Renal Drugs and the Drug Safety and Risk Management Advisory Committees

Meeting Date: September 11, 2007

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the discussions of updated information on risks and benefits of erythropoiesis-stimulating agents, when used in the treatment of anemia due to chronic renal failure, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Unrelated Data Safety Monitoring Board	Affected Firm	Less than \$10,001 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

 /S/
Signature of SGE

 07/27/07
Date